MindWalk reports platform validation with discovery targeting pathogenic TDP-43

MindWalk announced it has identified monoclonal antibodies and intrabodies that bind a pathogenic form of TDP‑43 and said this validates its discovery platform; the company noted the findings are preliminary and reported in a preprint.

MindWalk issued a press release reporting a discovery that it says validates the precision of its discovery platform. The company described identification of monoclonal antibodies and intrabodies that target a pathogenic form of the protein TDP‑43. TDP‑43 is discussed in the context of neurodegenerative disease research. The release also included standard forward-looking statements noting risks and uncertainties around these findings. Key points: - MindWalk reported identification of monoclonal antibodies and intrabodies that bind a pathogenic state of TDP‑43. - The company described this discovery as a validation of its discovery platform's precision. - The findings are described as preliminary and were reported in a preprint that has not undergone peer review. - The press release included forward-looking statements and listed risks such as reproducibility, safety, translation from preclinical work to clinical outcomes, intellectual property, and reliance on partners. Summary: The company framed the discovery as evidence of its platform’s ability to identify disease-related protein states while noting the results are preliminary and not yet peer reviewed. Undetermined at this time.